Jolanta MaÅ‚yszko

List of Publications by Year
in descending order

384	7,533	81900	88630
papers	citations	39 h-index	70 g-index

389	389	389	8962
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Haematological disorders following kidney transplantation. Nephrology Dialysis Transplantation, 2022, 37, 409-420.	0.7	6
2	Atherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. American Journal of Kidney Diseases, 2022, 79, 289-301.	1.9	18
3	Kidney Transplant Recipients Have Higher Malignancy Prevalence Than Hemodialyzed Patients. Transplantation Proceedings, 2022, 54, 972-975.	0.6	5
4	The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment. Medicina (Lithuania), 2022, 58, 417.	2.0	3
5	Malignancy Prevalence in the Dialyzed Population and in Waitlisted Potential Kidney Transplant Recipients. Transplantation Proceedings, 2022, , .	0.6	0
6	Chronic Kidney Disease in Patients After Allogeneic Hematopoietic Cell Transplant. Transplantation Proceedings, 2022, , .	0.6	0
7	Do Muslims Living in Poland Approve of Organ Transplantation?. Annals of Transplantation, 2022, 27, e934494.	0.9	0
8	Transgelin-2 in Multiple Myeloma: A New Marker of Renal Impairment?. Molecules, 2022, 27, 79.	3.8	4
9	Retroperitoneal Fibrosis Is Still an Underdiagnosed Entity with Poor Prognosis. Kidney and Blood Pressure Research, 2022, 47, 151-162.	2.0	5
10	Influence of formalized Predialysis Education Program (fPEP) on the chosen and definitive renal replacement therapy option. Advances in Clinical and Experimental Medicine, 2022, 31, 739-748.	1.4	4
11	Simultaneous Liver-Kidney Transplantation and the Use of Intraoperative Dialysis: A Monocenter Study. Transplantation Proceedings, 2022, , .	0.6	2
12	Retroperitoneal fibrosis, a rare entity with urorenal and vascular subtypes â€“ preliminary data. Renal Failure, 2022, 44, 688-692.	2.1	2
13	Increase Urinary Biomarkers of Kidney Injury in Patients After Allogenic Hematopoietic Stem Cell Transplant Reflect Kidney Damage Even in Normal Kidney Function. Transplantation Proceedings, 2022, 54, 1141-1144.	0.6	0
14	Should thorax thin section computed tomography (TSCT) be a standard diagnostic procedure in the evaluation of potential kidney transplant recipients - lessons learnt from COVID-19 pandemia. Transplantation Proceedings, 2022, , .	0.6	0
15	MO658: Effect of a Time-Dependent Dialysate Bicarbonate Concentration on Intradialytic and Postdialytic Blood Bicarbonate Kinetics. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	1
16	MO656: Validity of the Hydrogen Ion Mobilization Model During Haemodialysis with Time-Dependent Dialysate Bicarbonate Concentrations. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
17	Intraoperative dialysis with the use of a mobile dialysis system during liver transplantation. Advances in Medical Sciences, 2022, 67, 208-215.	2.1	2
18	Transplant Renal Artery Stenosis: Underrecognized, Not So Rare, but Curable Complication. Transplantation Proceedings, 2022, 54, 976-980.	0.6	1

#	Article	IF	Citations
19	Lack or insufficient predialysis nephrology care worsens the outcomes in dialyzed patients â€“ call for action. Renal Failure, 2022, 44, 946-957.	2.1	3
20	Main Barriers to the Introduction of a Home Haemodialysis Programme in Poland: A Review of the Challenges for Implementation and Criteria for a Successful Programme. Journal of Clinical Medicine, 2022, 11, 4166.	2.4	0
21	Post-transplant lymphoproliferative disorder: risk factors and management. Nephrology Dialysis Transplantation, 2021, 36, 1177-1179.	0.7	4
22	Same rhythm, different songâ€"approaches to atrial fibrillation management by cardiologists and nephrologists. CKJ: Clinical Kidney Journal, 2021, 14, 9-13.	2.9	0
23	Biomarkers of iron metabolism in chronic kidney disease. International Urology and Nephrology, 2021, 53, 935-944.	1.4	10
24	Intravenous iron therapy and the cardiovascular system: risks and benefits. CKJ: Clinical Kidney Journal, 2021, 14, 1067-1076.	2.9	12
25	Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. Nephrology Dialysis Transplantation, 2021, 37, ii33-ii44.	0.7	26
26	Kidney Function After Liver Transplantation in a Single Center. Annals of Transplantation, 2021, 26, e926928.	0.9	1
27	Nephrology in Poland. , 2021, , 593-606.		0
28	High-resolution computed tomography rather than chest radiography â€“ how pandemic changed our evaluation policy of potential kidney transplant recipients. Polish Archives of Internal Medicine, 2021, 131, 302-305.	0.4	1
29	The outcome of patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) and impaired kidney function: a 3-year observational study. International Urology and Nephrology, 2021, 53, 2557-2566.	1.4	6
30	Potential Effects of Immunosuppression on Oxidative Stress and Atherosclerosis in Kidney Transplant Recipients. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-10.	4.0	12
31	Uremic Toxins, Oxidative Stress, Atherosclerosis in Chronic Kidney Disease, and Kidney Transplantation. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-15.	4.0	35
32	Drug dosing in cancer patients with decreased kidney function: A practical approach. Cancer Treatment Reviews, 2021, 93, 102139.	7.7	8
33	Why albuminuria should be assessed more frequently in everyday clinical practice? Position statement. Polish Archives of Internal Medicine, 2021, 131, 396-406.	0.4	2
34	Primary Takotsubo Syndrome as a Complication of Bladder Cancer Treatment in a 62-Year-Old Woman. American Journal of Case Reports, 2021, 22, e930090.	0.8	3
35	Renal Replacement Modality Affects Uremic Toxins and Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-10.	4.0	1
36	Vitamin D deficiency and anemia is highly prevalent and dependent on the etiology of heart failure: A pilot study. Cardiology Journal, 2021, 28, 262-270.	1.2	6

#	Article	IF	Citations
37	MO128RETINOL BINDING PROTEIN (RBP) - NEW BIOMARKER OF KIDNEY INJURY IN MULTIPLE MYELOMA PATIENTS*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
38	May Measurement Month 2019: an analysis of blood pressure screening results from Poland. European Heart Journal Supplements, 2021, 23, B124-B127.	0.1	2
39	Exposure to air pollution and renal function. Scientific Reports, 2021, 11, 11419.	3.3	34
40	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2021, 99, 1280-1295.	5.2	103
41	Post-Contrast Acute Kidney Injury in Patients with Various Stages of Chronic Kidney Diseaseâ€"Is Fear Justified?. Toxins, 2021, 13, 395.	3.4	3
42	First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland. F1000Research, 2021, 10, 841.	1.6	1
43	Novel Iron Parameters in Patients with Type 2 Diabetes Mellitus in Relation to Kidney Function. Journal of Clinical Medicine, 2021, 10, 3732.	2.4	1
44	To Close, Observe, or Reconstruct: The Third Way of Managing Dialysis Fistula Aneurysms in Kidney Transplant Recipients. Journal of Clinical Medicine, 2021, 10, 4567.	2.4	2
45	Atrial Fibrillation and Chronic Kidney Diseaseâ€"A Risky Combination for Post-Contrast Acute Kidney Injury. Journal of Clinical Medicine, 2021, 10, 4140.	2.4	1
46	Current Status of Renal Anemia Pharmacotherapyâ€"What Can We Offer Today. Journal of Clinical Medicine, 2021, 10, 4149.	2.4	6
47	THE IMPORTANCE OF MENTAL RESILIENCE AGAINST LONELINESS DURING THE COVID-19 PANDEMIC IN DIALYSIS PATIENTS. WiadomoÅ›ci Lekarskie, 2021, 74, 1758-1762.	0.3	1
48	Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients. Cardiology Journal, 2021, , .	1.2	0
49	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. Nephrology Dialysis Transplantation, 2021, 37, ii14-ii23.	0.7	11
50	PostÄ™powanie z chorym z zespoÅ‚em stopy cukrzycowej â€“ wytyczne Polskiego Towarzystwa Leczenia Ran 2021: czÄ™Å›Ä‡ 1. Leczenie Ran, 2021, 18, 71-114.	0.2	1
51	NOVEL IRON BIOMARKERS IN CHRONIC KIDNEY DISEASE. WiadomoÅ›ci Lekarskie, 2021, 74, 3230-3233.	0.3	1
52	Cholecalciferol vs. Small Doses of Alfacalcidol vs. Placebo in Chronic Kidney Disease Patients on Hemodialysis: A Randomized Parallel Group Study. Frontiers in Medicine, 2021, 8, 781191.	2.6	3
53	Renal Impairment Detectors: IGFBP-7 and NGAL as Tubular Injury Markers in Multiple Myeloma Patients. Medicina (Lithuania), 2021, 57, 1348.	2.0	5
54	Early outcomes and long-term survival after kidney transplantation in elderly versus younger recipients from the same donor in a matched-pairs analysis. Medicine (United States), 2021, 100, e28159.	1.0	10

#	Article	IF	Citations
55	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 42-61.	5.2	260
56	FRAX prognostic and intervention thresholds in the management of major bone fractures in hemodialysis patients: A two-year prospective multicenter cohort study. Bone, 2020, 133, 115188.	2.9	6
57	Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 289-297.	4.5	50
58	Labile plasma iron levels in chronic hemodialysis patients treated by intravenous iron supplementation. Therapeutic Apheresis and Dialysis, 2020, 24, 416-422.	0.9	5
59	P0868ZONULIN AS A THERAPEUTIC POTENTIAL BIOMARKER OF ANEMIA IN PATIENTS WITH MULTIPLE MYELOMA AND CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
60	P0712TRANSGELIN AS A POTENTIAL MARKER OF RENAL IMPAIRMENT IN MULTIPLE MYELOMA PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
61	Opinions of Followers of Judaism Residing in the Northeastern Part of Poland on Organ Donation. Transplantation Proceedings, 2020, 52, 2895-2898.	0.6	1
62	May Measurement Month 2018: an analysis of blood pressure screening campaign results from Poland. European Heart Journal Supplements, 2020, 22, H108-H111.	0.1	4
63	Intraoperative Dialysis During Liver Transplantation. Transplantation Proceedings, 2020, 52, 2454-2458.	0.6	6
64	Organ Procurement in Poland: Legal and Medical Aspects. Transplantation Proceedings, 2020, 52, 2015-2025.	0.6	1
65	P0005TIME-VARYING DIALYSATE BICARBONATE CONCENTRATIONS CAN REDUCE PEAK INTRADIALTIC SERUM BICARBONATE CONCENTRATIONS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
66	Impact of chronic kidney disease on long-term outcome of patients with valvular heart defects. International Urology and Nephrology, 2020, 52, 2161-2170.	1.4	4
67	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney International, 2020, 98, 1407-1418.	5.2	8
68	Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma. Mediators of Inflammation, 2020, 2020, 1-13.	3.0	4
69	The link between kidney disease and cancer: complications and treatment. Lancet, The, 2020, 396, 277-287.	13.7	71
70	P0624INCREASED URINARY BIOMARKERS OF KIDNEY INJURY IN PATIENTS AFTER ALLOGENETICHEMATOPOETIC STEM CELL TRANSPLANTATION REFLECT KIDNEY DAMAGE EVEN IN NORMALN KIDNEY FUNCTION. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
71	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, andÂmanaging kidney cancer. Kidney International, 2020, 98, 1108-1119.	5.2	26
72	Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference. European Journal of Emergency Medicine, 2020, 27, 329-337.	1.1	46

#	Article	IF	Citations
73	Impact of renal function on patients with acute coronary syndromes: 15,593 patient-years study. Renal Failure, 2020, 42, 881-889.	2.1	10
74	Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study. Journal of Hypertension, 2020, 38, 1849-1856.	0.5	15
75	Iron and Chronic Kidney Disease: Still a Challenge. Frontiers in Medicine, 2020, 7, 565135.	2.6	14
76	P0627INTRAOPERATIVE DIALYSIS DURING LIVER TRANSPLANTATION IS SAFE AND BENEFICIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
77	P0745URINE TIMP-2 AND IGFBP-7- NEW BIOMARKERS OF KIDNEY INJURY IN MULTIPLE MYELOMA PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
78	P1115MEDICAL WASTE MANAGEMENT - HOW INDUSTRY CAN HELP US TO PROTECT ENVIRONMENT AND MONEY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
79	Renal Involvement in Systemic Sclerosis: An Update. Kidney and Blood Pressure Research, 2020, 45, 532-548.	2.0	38
80	Knowledge of Law Students on the Problems of Modern Transplantology Is Good but It Can Always Be Better. Transplantation Proceedings, 2020, 52, 1985-1990.	0.6	1
81	Malignancy Prevalence in Waitlisted Potential Kidney Transplant Recipients Is Very Low Relative to Patients After Kidney Transplantation. Transplantation Proceedings, 2020, 52, 2264-2267.	0.6	3
82	New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies. Journal of Clinical Medicine, 2020, 9, 1652.	2.4	9
83	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. American Journal of Kidney Diseases, 2020, 76, 109-120.	1.9	10
84	Kidney biopsy in patients after liver transplantation: an underutilized, but clinically important procedure. International Urology and Nephrology, 2020, 52, 1191-1192.	1.4	3
85	Takotsubo syndrome â€“ fatal prognosis of patients with low body mass index in 5-year follow-up. Archives of Medical Science, 2020, 16, 282-288.	0.9	10
86	The Serum Concentration of Anti-Aging Proteins, Sirtuin1 and Î±Klotho in Patients with End-Stage Kidney Disease on Maintenance Hemodialysis . Clinical Interventions in Aging, 2020, Volume 15, 387-393.	2.9	11
87	How to assess kidney function in oncology patients. Kidney International, 2020, 97, 894-903.	5.2	9
88	Iron, ferroptosis, and new insights for prevention in acute kidney injury. Advances in Medical Sciences, 2020, 65, 361-370.	2.1	29
89	Real-world prognostic factors in autotransplanted multiple myeloma patients with severe renal impairment: study of the Polish Myeloma Study Group. Archives of Medical Science, 2020, , .	0.9	1
90	Medical waste management â€“ how industry can help us to protect environment and money?. Renal Failure, 2020, 42, 547-549.	2.1	5

#	Article	IF	Citations
91	SAT-107 BLOOD PRESSURE TARGET IS FAR BEING REACHED IN HEMODIALYZED PATIENTS AS PER CURRENT GUIDELINES. Kidney International Reports, 2020, 5, S47-S48.	0.8	0
92	Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. Nephrology Dialysis Transplantation, 2020, 35, 1761-1769.	0.7	5
93	Eco-dialysis: fashion or necessity. International Urology and Nephrology, 2020, 52, 519-523.	1.4	9
94	Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant. Transplantation Proceedings, 2020, 52, 2186-2192.	0.6	3
95	Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2020, 98, 294-309.	5.2	254
96	Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress. Kidney and Blood Pressure Research, 2020, 45, 645-660.	2.0	31
97	Acute kidney injury, its definition, and treatment in adults: guidelines and reality. Polish Archives of Internal Medicine, 2020, 130, 1074-1080.	0.4	13
98	Hypotensive Syndromes and Chronic Kidney Disease. , 2020, , 129-138.		0
99	Diagnosis and recovery from SARS-CoV-2 infection is challenging in kidney patients: tests are an issue. Polish Archives of Internal Medicine, 2020, 130, 463-465.	0.4	1
100	Post-contrast acute kidney injury following contrast enhanced computed tomography: real or overestimated threat?. Polish Archives of Internal Medicine, 2020, 130, 704-707.	0.4	1
101	Association of FGF19, FGF21 and FGF23 with carbohydrate metabolism parameters and insulin resistance in patients with chronic kidney disease. Journal of Applied Biomedicine, 2020, 18, 61-69.	1.7	1
102	HEMATURIA AND OTHER KINDS OF BLEEDINGS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: AN UPDATED OVERVIEW ON OCCURRENCE, PATHOMECHANISMS AND MANAGEMENT. WiadomoÅ›ci Lekarskie, 2020, 73, 2528-2534.	0.3	1
103	HOME DIALYSIS DURING COVID-19 OUTBREAKâ€“ IT IS WORTH TO CONSIDER. WiadomoÅ›ci Lekarskie, 2020, 73, 2316-2318.	0.3	1
104	RHABDOMYOLYSIS â€“ INDUCED ACUTE KIDNEY INJURY â€“ AN UNDERESTIMATED PROBLEM. WiadomoÅ›ci Lekarskie, 2020, 73, 2543-2548.	0.3	7
105	COMPARISON OF MOLECULAR AND SEROLOGICAL TESTS FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) IN POST-EXPOSURE EMPLOYEES OF THE NEPHROLOGY DEPARTMENT. WiadomoÅ›ci Lekarskie, 2020, 73, 2572-2575.	0.3	0
106	CANCER IN DIALYSIS PATIENTS. WiadomoÅ›ci Lekarskie, 2020, 73, 2068-2072.	0.3	0
107	Clinical Relevance of Kidney Biopsy in Patients Qualified for Liver Transplantation and After This Procedure in the Model for End-stage Liver Disease (MELD) Era: Where Are We Today?. Annals of Transplantation, 2020, 25, e925891.	0.9	0
108	Clinical Relevance of Kidney Biopsy in Patients Qualified for Liver Transplantation and After This Procedure in the Model for End-stage Liver Disease (MELD) Era: Where Are We Today?. Annals of Transplantation, 2020, 25, e925891.	0.9	4

#	Article	IF	Citations
109	CANCER IN DIALYSIS PATIENTS. WiadomoÅ›ci Lekarskie, 2020, 73, 2068-2072.	0.3	0
110	New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia. Journal of Clinical Medicine, 2019, 8, 1828.	2.4	12
111	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 836-849.	5.2	80
112	State of the art â€“ sirtuin 1 in kidney pathology â€“ clinical relevance. Advances in Medical Sciences, 2019, 64, 356-364.	2.1	9
113	The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance. Nephrology Dialysis Transplantation, 2019, 34, 1440-1452.	0.7	10
114	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney International, 2019, 96, 555-567.	5.2	47
115	Peritoneal Ultrafiltration in the Long-Term Treatment of Chronic Heart Failure Refractory to Pharmacological Therapy. Frontiers in Physiology, 2019, 10, 310.	2.8	11
116	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. European Heart Journal, 2019, 40, 2006-2017.	2.2	193
117	Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opinion on Therapeutic Targets, 2019, 23, 407-421.	3.4	21
118	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrology Dialysis Transplantation, 2019, 34, 208-230.	0.7	147
119	Hepcidin â€“ Potential biomarker of contrast-induced acute kidney injury in patients undergoing percutaneous coronary interventions. Advances in Medical Sciences, 2019, 64, 211-215.	2.1	5
120	Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Studyâ€”A Comparison. Frontiers in Endocrinology, 2019, 10, 40.	3.5	6
121	Hypertension prevalence in early breast cancer patients undergoing primary surgery. Advances in Medical Sciences, 2019, 64, 32-36.	2.1	5
122	Urinary and Serum Biomarkers for Prediction of Acute Kidney Injury in Patients Undergoing Liver Transplantation. Annals of Transplantation, 2019, 24, 291-297.	0.9	14
123	Hypertension and chronic kidney disease is highly prevalent in elderly patients with colorectal cancer undergoing primary surgery. Advances in Clinical and Experimental Medicine, 2019, 28, 1425-1428.	1.4	6
124	Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease. Advances in Clinical and Experimental Medicine, 2019, 28, 1571-1575.	1.4	39
125	Toxic epidermal necrolysis (Lyell syndrome) as a severe and fatal manifestation of multiple myeloma with amyloidosis in patient with rapidly developing end-stage kidney disease. Polish Archives of Internal Medicine, 2019, 129, 819-821.	0.4	1
126	Viruses in transplantology. Polish Archives of Internal Medicine, 2019, 129, 1-36.	0.4	1

#	Article	IF	Citations
127	Kidney and Inferior vena cava abnormalities and Leg Thrombosis (KILT) syndrome in a young man mimicking retroperitoneal lymphoma. Polish Archives of Internal Medicine, 2019, 130, 75-76.	0.4	0
128	Hypertension in patients with acute kidney injury. WiadomoÅ›ci Lekarskie, 2019, 72, 2199-2201.	0.3	1
129	Endocan Concentration in Kidney Transplant Recipients. Transplantation Proceedings, 2018, 50, 1798-1801.	0.6	6
130	Opinions and Attitudes of Medical Students About Organ Donation and Transplantation. Transplantation Proceedings, 2018, 50, 1939-1945.	0.6	14
131	Underrecognition and Underestimation of Disturbances in Calcium-Phosphate Balance in Kidney Transplant Recipients. Transplantation Proceedings, 2018, 50, 1790-1793.	0.6	4
132	Future Lawyers Support Organ Donation and Transplantation. Transplantation Proceedings, 2018, 50, 1946-1952.	0.6	3
133	Atrial fibrillation in kidney transplant recipients: is there a place for the novel drugs?. Nephrology Dialysis Transplantation, 2018, 33, 1304-1309.	0.7	24
134	Endocan Concentration in Patients With Primary Hypertension. Angiology, 2018, 69, 483-489.	1.8	26
135	Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs. Expert Review of Clinical Pharmacology, 2018, 11, 165-170.	3.1	15
136	Bleeding in advanced CKD patients on antithrombotic medication â€“ A critical appraisal. Pharmacological Research, 2018, 129, 535-543.	7.1	16
137	Zonulin, inflammation and iron status in patients with early stages of chronic kidney disease. International Urology and Nephrology, 2018, 50, 121-125.	1.4	18
138	Patients with atrial fibrillation and coronary artery disease â€“ Double trouble. Advances in Medical Sciences, 2018, 63, 30-35.	2.1	142
139	Lipid management in patients with chronic kidney disease. Nature Reviews Nephrology, 2018, 14, 727-749.	9.6	153
140	Hypertension in malignancy-an underappreciated problem. Oncotarget, 2018, 9, 20855-20871.	1.8	18
141	Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?. International Urology and Nephrology, 2018, 50, 1633-1642.	1.4	3
142	Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment?. Postgraduate Medicine, 2018, 130, 461-469.	2.0	11
143	The prevalence of hepatitis C and B among patients on hemodialysis and on renal transplantation waiting list in Poland has significantly decreased during the last 10Âyears. International Urology and Nephrology, 2018, 50, 1555-1556.	1.4	3
144	Eye Problems in Patients on the Active and Inactive Kidney Transplantation Waiting List. Transplantation Proceedings, 2018, 50, 1634-1636.	0.6	6

#	Article	IF	Citations
145	Progression to chronic kidney disease in patients undergoing nephrectomy for small renal masses: a price to pay for a therapeutic success?. Postgraduate Medicine, 2018, 130, 613-620.	2.0	1
146	Cardiovascular Outcomes Reported in Hemodialysis Trials. Journal of the American College of Cardiology, 2018, 71, 2802-2810.	2.8	16
147	ERA-EDTA invests in transformation to greener health care. Nephrology Dialysis Transplantation, 2018, 33, 901-903.	0.7	21
148	Endothelium, asymmetric dimethylarginine, and atherosclerosis in chronic kidney disease. Polish Archives of Internal Medicine, 2018, 128, 145-147.	0.4	6
149	Takotsubo syndrome and chronic kidney disease - deadly duet in long-term follow-up. Polish Archives of Internal Medicine, 2018, 128, 518-523.	0.4	8
150	The Potential Impact of Sirtuin 1 Protein on Premature Ovarian Insufficiency. Current Proteomics, 2018, 15, 208-213.	0.3	1
151	Nephrotoxicity of anticancer treatment. Nephrology Dialysis Transplantation, 2017, 32, gfw338.	0.7	80
152	Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant. International Urology and Nephrology, 2017, 49, 875-879.	1.4	0
153	Amyloidosis: A cancer-derived paraproteinemia and kidney involvement. Advances in Medical Sciences, 2017, 62, 31-38.	2.1	3
154	Matrix Metalloproteinase Neutrophil Gelatinase-Associated Lipocalin Complex Predicts Atrial Fibrillation Recurrence after Electrical Cardioversion in Obese Patients. CardioRenal Medicine, 2017, 7, 11-20.	1.9	5
155	Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project. Advances in Medical Sciences, 2017, 62, 405-413.	2.1	18
156	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2017, 32, 1967-1976.	0.7	14
157	Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients. CKJ: Clinical Kidney Journal, 2017, 10, i25-i31.	2.9	8
158	Fibroblast growth factor 23, iron and inflammation â€“ are they related in early stages of chronic kidney disease?. Archives of Medical Science, 2017, 4, 845-850.	0.9	12
159	Hyperglycemia and diabetes have different impacts on outcome of ischemic and hemorrhagic stroke. Archives of Medical Science, 2017, 1, 100-108.	0.9	38
160	MP621THE RELATIONSHIP BETWEEN RENALASE TOGETHER WITH CATECHOLAMINES AND ANTI-AGING FACTORS - SIRTUIN 1 AND ALPHA-KLOTHO IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2017, 32, iii661-iii662.	0.7	0
161	MP114THE CONCENTRATION OF ADROPIN AND IRISIN IN PATIENTS WITH PRIMARY HYPERTENSION. Nephrology Dialysis Transplantation, 2017, 32, iii470-iii470.	0.7	0
162	Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?. Oncotarget, 2017, 8, 66601-66619.	1.8	22

#	Article	IF	Citations
163	Telomere attrition, kidney function, and prevalent chronic kidney disease in the United States. Oncotarget, 2017, 8, 80175-80181.	1.8	34
164	Does combination of paricalcitol with cinacalcet in secondary hyperparathyroidism in hemodialysis treatment make sense?. Polish Archives of Internal Medicine, 2017, 127, 840-845.	0.4	3
165	Endothelial Dysfunction and Nitric Oxide: Albuminuria as a Central Marker. , 2017, , 3-9.		0
166	Immune biomarkers: do they impact long-term graft survival?. Polish Archives of Internal Medicine, 2017, 127, 149-151.	0.4	0
167	SP116ENDOCAN CONCENTRATION IN HYPERTENSIVE PATIENTS. Nephrology Dialysis Transplantation, 2016, 31, i124-i124.	0.7	0
168	Age influence on renalase and catecholamines concentration in hypertensive patients, including maintained dialysis. Clinical Interventions in Aging, 2016, Volume 11, 1545-1550.	2.9	15
169	Effects of dialyzer reuse on dialysis adequacy, anemia control, erythropoieting-stimulating agents use and phosphate level. Archives of Medical Science, 2016, 1, 219-221.	0.9	1
170	Comorbidities on kidney transplantation waiting list relative to the status of the potential recipient. Archives of Medical Science, 2016, 14, 941-944.	0.9	5
171	GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients. International Urology and Nephrology, 2016, 48, 839-844.	1.4	20
172	Prospective Assessment of Hepcidin in Relation to Delayed or Immediate Graft Function in Patients Undergoing Kidney Transplantation. Transplantation Proceedings, 2016, 48, 1506-1510.	0.6	3
173	Renal Function Predicts Outcomes in Patients with Ischaemic Stroke and Haemorrhagic Stroke. Kidney and Blood Pressure Research, 2016, 41, 424-433.	2.0	24
174	Do Age and Religion Have an Impact on the Attitude to Organ Transplantation?. Transplantation Proceedings, 2016, 48, 1354-1359.	0.6	15
175	Emerging drugs for the treatment of kidney disease-induced anemia. Expert Opinion on Emerging Drugs, 2016, 21, 315-330.	2.4	7
176	OS 01-02 ENDOCAN LEVEL IN ESSENTIAL HYPERTENSION. Journal of Hypertension, 2016, 34, e44.	0.5	0
177	MPS 05-05 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY MEASURED METABOLITES OF ENDOGENOUS CATECHOLAMINES AND THEIR RELATIONS TO CHRONIC KIDNEY DISEASE AND HIGH BLOOD PRESSURE IN HEART TRANSPLANT RECIPIENTS. Journal of Hypertension, 2016, 34, e91.	0.5	0
178	Renalase â€" a new marker or just a bystander in cardiovascular disease: clinical and experimental data. Kardiologia Polska, 2016, 74, 937-942.	0.6	6
179	Management of patients with atrial fibrillation and chronic kidney disease in light of the latest guidelines. Polish Archives of Internal Medicine, 2016, 126, 353-362.	0.4	6
180	Problemy nefrologiczne u pacjentÃ³w zakaÅ¼onych HIV. Forum ZakaÅ¼eÅ„, 2016, 7, 225-231.	0.0	0

#	Article	IF	Citations
181	Internal medicine: I cannot live without you as you are my destiny. Polish Archives of Internal Medicine, 2016, 126, 1060-1061.	0.4	0
182	Circulating renalase, catecholamines, and vascular adhesionÂprotein 1 in hypertensive patients. Journal of the American Society of Hypertension, 2015, 9, 855-864.	2.3	22
183	Do CHA₂DS₂VASc and HASâ€BLED scores influence â€˜realâ€worldâ€™ anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre. Pharmacoepidemiology and Drug Safety, 2015, 24, 1297-1303.	1.9	6
184	Letter to the Editor Chronic kidney disease in patients with significant left main coronary artery disease qualified for coronary artery bypass graft operation. Archives of Medical Science, 2015, 2, 446-452.	0.9	4
185	State of the art paper Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems. Archives of Medical Science, 2015, 1, 67-77.	0.9	167
186	Midkine: A Novel and Early Biomarker of Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions. BioMed Research International, 2015, 2015, 1-5.	1.9	20
187	FP797ENDOCAN SERUM LEVELS IN HEMODIALYSIS PATIENTS BEFORE AND DURING THE PROCEDURE WITH TWO DIFFERENT DIALYSIS MEMBRANES. Nephrology Dialysis Transplantation, 2015, 30, iii343-iii343.	0.7	0
188	SP814RENAL TRANSPLANTATION IN ELDERLY PATIENTS-POLISH MULTICENTRE STUDY. Nephrology Dialysis Transplantation, 2015, 30, iii647-iii647.	0.7	0
189	Renalase is Removed by Kidneys and During Dialysis â€“ Excess Related to CKD Complications?. Current Vascular Pharmacology, 2015, 13, 134-140.	1.7	8
190	The growth of acute kidney injury: Eastern European perspective. Kidney International, 2015, 87, 1264.	5.2	4
191	Iron Status and Inflammation in Early Stages of Chronic Kidney Disease. Kidney and Blood Pressure Research, 2015, 40, 366-373.	2.0	43
192	The fate of triaged and rejected manuscripts. Nephrology Dialysis Transplantation, 2015, 30, 1947-1950.	0.7	9
193	Copeptin: Pathophysiology and potential clinical impact. Advances in Medical Sciences, 2015, 60, 335-341.	2.1	33
194	Biomarkers of delayed graft function as a form of acute kidney injury in kidney transplantation. Scientific Reports, 2015, 5, 11684.	3.3	52
195	Cardiorenal Syndrome and the Role of the Bone-Mineral AxisÂandÂAnemia. American Journal of Kidney Diseases, 2015, 66, 196-205.	1.9	38
196	Drug Evaluation: Olmesartan Medoxomil + Rosuvastatin for the Treatment of Dyslipidemia and Concomitant Risk Factors: A Chance for Better Compliance?. , 2015, , 191-200.		1
197	Cardiovascular evaluation of potential transplant recipient: from non-US perspective. Kidney International, 2015, 87, 863.	5.2	0
198	Renalase, kidney and cardiovascular disease: Are they related or just coincidentally associated?. Advances in Medical Sciences, 2015, 60, 41-49.	2.1	22

#	Article	IF	Citations
199	Iron metabolism in chronic kidney disease. , 2015, , .		1
200	Opinions and Knowledge about Organ Donation and Transplantation of Residents of Selected Villages in Podlaskie Voivodeship. Annals of Transplantation, 2015, 20, 256-262.	0.9	3
201	Management of patients with valvular and non-valvular atrial fibrillation in Poland: Results from Reference Cardiology University Center. Cardiology Journal, 2015, 22, 296-305.	1.2	3
202	Organ transplantation â€“ the view of healthcare employees. PostÄ™py Nauk Medycznych, 2015, 28, 698-703.	0.0	0
203	Iron metabolism in hemodialyzed patients â€“ aÂstory half told?. Archives of Medical Science, 2014, 6, 1117-1122.	0.9	12
204	Use of short prosthesis segments for brachiocephalic arteriovenous fistulas in elderly hemodialysis population. Archives of Medical Science, 2014, 1, 58-62.	0.9	1
205	Is There Association Between Changes in eGFR Value and the Risk of Permanent Type of Atrial Fibrillation? - Analysis of Valvular and Non-Valvular Atrial Fibrillation Population. Kidney and Blood Pressure Research, 2014, 39, 600-608.	2.0	5
206	New renal anemia drugs: is there really anything new on the horizon?. Expert Opinion on Emerging Drugs, 2014, 19, 1-4.	2.4	8
207	Basilic Vein Transposition in the Forearm for Secondary Arteriovenous Fistula. Angiology, 2014, 65, 330-332.	1.8	11
208	Renal anaemia treatment in haemodialysis patients in the Central and Eastern European countries in everyday clinical practice follow-up. International Urology and Nephrology, 2014, 46, 71-82.	1.4	1
209	YKL-40, a Marker of Cardiovascular Disease and Endothelial Dysfunction, in Kidney Transplant Recipients. Transplantation Proceedings, 2014, 46, 2651-2653.	0.6	9
210	Opinions of Town Residents on Organ Transplantation. Transplantation Proceedings, 2014, 46, 2492-2495.	0.6	6
211	Attitudes of Members of the Baptist Church Toward Organ Transplantation. Transplantation Proceedings, 2014, 46, 2487-2491.	0.6	7
212	FGF23 and Klotho in Relation to Markers of Endothelial Dysfunction in Kidney Transplant Recipients. Transplantation Proceedings, 2014, 46, 2647-2650.	0.6	26
213	Zonulin, Iron Status, and Anemia in Kidney Transplant Recipients: Are They Related?. Transplantation Proceedings, 2014, 46, 2644-2646.	0.6	15
214	Biomarkers of Contrast-Induced Nephropathy. Interventional Cardiology Clinics, 2014, 3, 379-391.	0.4	3
215	New therapeutic perspectives on protein-bound uremic toxins in chronic kidney disease. Expert Opinion on Therapeutic Targets, 2014, 18, 109-113.	3.4	2
216	Serum adiponectin and markers of endothelial dysfunction in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG). Advances in Medical Sciences, 2014, 59, 245-249.	2.1	9

#	Article	IF	Citations
217	Impact of diabetes on mortality and complications after coronary artery by-pass graft operation in patients with left main coronary artery disease. Advances in Medical Sciences, 2014, 59, 250-255.	2.1	9
218	Cardiovascular disease and kidney transplantationâ€‘evaluation of potential transplant recipient. Polish Archives of Internal Medicine, 2014, 124, 608-616.	0.4	8
219	Pre-CKD- Do we Need Another Hero?. Current Vascular Pharmacology, 2014, 12, 642-648.	1.7	4
220	Peritoneal ultrafiltration in end-stage congestive heart failure. Cardiology Journal, 2014, 21, 115-120.	1.2	4
221	Pedometer assessed physical activity of people with metabolic syndrome in Poland.. Annals of Agricultural and Environmental Medicine, 2014, 21, 353-358.	1.0	7
222	Patients with Prehypertension â€“ Do we have Enough Evidence to Treat them?. Current Vascular Pharmacology, 2014, 12, 586-597.	1.7	3
223	GDF15 Is Related to Anemia and Hepcidin in Kidney Allograft Recipients. Nephron Clinical Practice, 2013, 123, 112-117.	2.3	22
224	Cardiac device-related endocarditis in the patient with end-stage renal failure in the course of Fabry disease. International Urology and Nephrology, 2013, 45, 1533-1535.	1.4	0
225	Renalase, Hypertension, and Kidney â€” The Discussion Continues. Angiology, 2013, 64, 181-187.	1.8	18
226	A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. International Journal of Cardiology, 2013, 168, 5437-5447.	1.7	66
227	Blood Pressure Levels and Stroke: J-curve Phenomenon?. Current Hypertension Reports, 2013, 15, 575-581.	3.5	26
228	Pharmacologic Treatment in Dialysis Patients Hospitalized for Cardiovascular Reasons: Do We Follow the Guidelines?. Renal Failure, 2013, 35, 235-242.	2.1	5
229	Vascular Adhesion Protein-1, a Novel Molecule, in Kidney and Heart Allograft Recipients. Transplantation Proceedings, 2013, 45, 2009-2012.	0.6	4
230	Circulating Levels of Renalase, Norepinephrine, and Dopamine in Dialysis Patients. Renal Failure, 2013, 35, 673-679.	2.1	34
231	Iron status in patients with chronic heart failure. European Heart Journal, 2013, 34, 827-834.	2.2	212
232	Antibodies against NÎµ-homocysteinylated proteins in patients on different methods of renal replacement therapy. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1093-9.	2.3	1
233	Does Neutrophil Gelatinase-Asociated Lipocalin Have Prognostic Value in Patients with Stable Angina Undergoing Elective PCI? A 3-Year Follow-Up Study. Kidney and Blood Pressure Research, 2013, 37, 280-285.	2.0	3
234	Letter on â€˜Sodium-dependent modulation of systemic and urinary renalase expression and activity in the rat remnant kidneyâ€™. Journal of Hypertension, 2013, 31, 1272-1273.	0.5	3

#	Article	IF	Citations
235	Renal replacement therapy before, during, and after orthotopic liver transplantation. Annals of Transplantation, 2013, 18, 248-255.	0.9	27
236	VAP-1 in peritoneally dialyzed patients. Postepy Higieny I Medycyny Doswiadczalnej, 2013, 67, 1340-1344.	0.1	1
237	VAP-1, a Novel Molecule Linked to Endothelial Damage and Kidney Function in Kidney Allograft Recipients. Kidney and Blood Pressure Research, 2012, 36, 242-247.	2.0	15
238	Renalase in Peritoneal Dialysis Patients is Not Related to Blood Pressure, but to Dialysis Vintage. Peritoneal Dialysis International, 2012, 32, 348-351.	2.3	34
239	Renal Anemia Treatment with ESA in Hemodialysis Patients in Relation to Early versus Late Referral in Everyday Clinical Practice in Central and Eastern European Countries: Baseline Data. Kidney and Blood Pressure Research, 2012, 35, 58-67.	2.0	3
240	Hypertension and kidney disease. Journal of Hypertension, 2012, 30, 457-462.	0.5	20
241	Vascular adhesion protein-1 and renalase in regard to diabetes in hemodialysis patients. Archives of Medical Science, 2012, 6, 1048-1052.	0.9	23
242	Renalase, Stroke, and Hypertension in Hemodialyzed Patients. Renal Failure, 2012, 34, 727-731.	2.1	36
243	Is hemojuvelin a possible new player in iron metabolism in hemodialysis patients?. International Urology and Nephrology, 2012, 44, 1805-1811.	1.4	11
244	Hepatocyte Growth Factor in Saliva of Patients with Renal Failure and Periodontal Disease. Renal Failure, 2012, 34, 942-951.	2.1	9
245	Angiographically-Derived SYNTAX Score and Its Prognostic Value in Dialysis Patients: Comparison With the Khan Index. Canadian Journal of Cardiology, 2012, 28, 450-457.	1.7	8
246	Prevention of sudden cardiac death in patients with chronic kidney disease. BMC Nephrology, 2012, 13, 162.	1.8	27
247	Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrology Dialysis Transplantation, 2012, 27, 3923-3929.	0.7	20
248	Renalase, a Novel Enzyme Involved in Blood Pressure Regulation, Is Related to Kidney Function but Not to Blood Pressure in Hemodialysis Patients. Kidney and Blood Pressure Research, 2012, 35, 395-399.	2.0	51
249	Serum Hemojuvelin and Hepcidin Levels in Chronic Kidney Disease. American Journal of Nephrology, 2012, 35, 295-304.	3.1	24
250	Prosthetic status and treatment needs for lost masticatory function in haemodialysis patients. Archives of Medical Science, 2012, 1, 81-87.	0.9	5
251	Left ventricular morphology and function in diabetic and nondiabetic hemodialyzed patients. Hemodialysis International, 2012, 16, 259-265.	0.9	2
252	Anemia and Erythrocytosis in patients after kidney transplantation. Transplant International, 2012, 25, 1013-1023.	1.6	42

#	Article	IF	Citations
253	Anemia in solid organ transplantation. Annals of Transplantation, 2012, 17, 86-100.	0.9	32
254	Renalase, kidney function, and markers of endothelial dysfunction in renal transplant recipients. Polish Archives of Internal Medicine, 2012, 122, 40-44.	0.4	18
255	Kidney and hypertension: is there a place for renalase?. Polish Archives of Internal Medicine, 2012, 122, 174-179.	0.4	3
256	New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis. Polish Archives of Internal Medicine, 2012, 122, 537-542.	0.4	8
257	Lipids, Blood Pressure, Kidney-what was New in 2012?. International Journal of Pharmacology, 2012, 8, 659-678.	0.3	9
258	Do overweight patients have a better five years prognosis after an acute myocardial infarction treated with coronary intervention?. Kardiologia Polska, 2012, 70, 686-93.	0.6	4
259	New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis. , 2012, 122, 537-42.		8
260	Iron metabolism in solidâ€'organ transplantation: how far are we from solving the mystery?. , 2012, 122, 504-11.		4
261	Which Method of GFR Estimation Has the Best Prognostic Value in Patients Treated with Primary PCI: Cockcroftâ€"Gault Formula, MDRD, or CKD-EPI Equation?â€"A 6-Year Follow-Up. Renal Failure, 2011, 33, 983-989.	2.1	19
262	Does Lack of ST-Segment Resolution Still Have Prognostic Value 6 Years After an Acute Myocardial Infarction Treated With Coronary Intervention?. Canadian Journal of Cardiology, 2011, 27, 573-580.	1.7	7
263	Renalase, A Novel Regulator of Blood Pressure, Is Predicted by Kidney Function in Renal Transplant Recipients. Transplantation Proceedings, 2011, 43, 3004-3007.	0.6	55
264	Iron Metabolism in Kidney Allograft Recipients: Still a Mystery?. Transplantation Proceedings, 2011, 43, 2973-2975.	0.6	4
265	Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate. Archives of Medical Science, 2011, 4, 658-664.	0.9	28
266	State of the art papers Lipids, blood pressure, kidney â€" what was new in 2011?. Archives of Medical Science, 2011, 6, 1055-1066.	0.9	63
267	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Is a Marker of Kidney Function and Inflammation in Heart and Kidney Transplant Recipients. Transplantation Proceedings, 2011, 43, 1877-1880.	0.6	10
268	Type of arteriovenous fistula, NYHA class and apelin in hemodialyzed patients. International Urology and Nephrology, 2011, 43, 185-190.	1.4	9
269	Comparative Analysis of the New Chronic Kidney Disease Epidemiology Collaboration and the Modification of Diet in Renal Disease Equations for Estimation of Glomerular Filtration Rate in HIV Type 1-Infected Subjects. AIDS Research and Human Retroviruses, 2011, 27, 809-813.	1.1	8
270	Copeptin and Its Relation to Arteriovenous Fistula (AVF) Type and NYHA Class in Hemodialysis Patients. Renal Failure, 2011, 33, 929-934.	2.1	4

#	Article	IF	Citations
271	Impact of Diabetes Mellitus on Survival in Patients with End-Stage Renal Disease: A Three-Year Follow-Up. Kidney and Blood Pressure Research, 2011, 34, 83-86.	2.0	8
272	What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist?. Expert Opinion on Pharmacotherapy, 2011, 12, 1835-1844.	1.8	31
273	Apelin: a novel marker for the patients with first ST-elevation myocardial infarction. Heart and Vessels, 2010, 25, 363-367.	1.2	33
274	Visfatin and endothelial function in dialyzed patients. Nephrology, 2010, 15, 190-196.	1.6	19
275	The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients. Archives of Medical Science, 2010, 4, 539-544.	0.9	20
276	Serum neutrophil gelatinase-associated lipocalin as a marker of kidney function in pregnancy â€“ useful or doubtful?. Archives of Medical Science, 2010, 5, 744-747.	0.9	5
277	Possible Relationship between Neutrophil Gelatinase-Associated Lipocalin, Hepcidin, and Inflammation in Haemodialysed Patients. Nephron Clinical Practice, 2010, 115, c268-c275.	2.3	15
278	Biomarkers of Acute Kidney Injury in Different Clinical Settings: A Time to Change the Paradigm. Kidney and Blood Pressure Research, 2010, 33, 368-382.	2.0	47
279	Current Status of the Measurement of Blood Hepcidin Levels in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1681-1689.	4.5	72
280	Coronary blood flow in patients with end-stage renal disease assessed by thrombolysis in myocardial infarction frame count method. Nephrology Dialysis Transplantation, 2010, 25, 926-930.	0.7	13
281	Mechanism of endothelial dysfunction in chronic kidney disease. Clinica Chimica Acta, 2010, 411, 1412-1420.	1.1	176
282	Prevalence of Chronic Kidney Disease in Orthotopic Heart Transplant Recipients and Kidney Allograft Recipients Using the New Chronic Kidney Disease Epidemiology Collaboration Formula. Transplantation Proceedings, 2010, 42, 4251-4254.	0.6	10
283	Kidney Injury Molecule-1 Correlates With Kidney Function in Renal Allograft Recipients. Transplantation Proceedings, 2010, 42, 3957-3959.	0.6	31
284	Neutrophil Gelatinase-Associated Lipocalin and Hepcidin: What Do They Have in Common and Is There a Potential Interaction?. Kidney and Blood Pressure Research, 2010, 33, 157-165.	2.0	26
285	Perfusion defects on real-time myocardial contrast echocardiography predict higher mortality in patients with end-stage renal disease â€“ A 3-year follow-up. Renal Failure, 2010, 32, 1160-1166.	2.1	2
286	Prevalence of chronic kidney disease and anemia in patients with coronary artery disease with normal serum creatinine undergoing percutaneous coronary interventions: relation to New York Heart Association class. Israel Medical Association Journal, 2010, 12, 489-93.	0.1	8
287	Serum Prohepcidin and Hepcidin in Hemodialyzed Patients Undergoing Iron Therapy. Kidney and Blood Pressure Research, 2009, 32, 235-238.	2.0	16
288	Hemojuvelin: The Hepcidin Story Continues. Kidney and Blood Pressure Research, 2009, 32, 71-76.	2.0	24

#	Article	IF	Citations
289	Serum Neutrophil Gelatinase-Associated Lipocalin as a Marker of Renal Function in Patients with Chronic Heart Failure and Coronary Artery Disease. Kidney and Blood Pressure Research, 2009, 32, 77-80.	2.0	84
290	Hepcidin Assays. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1015-1016.	4.5	30
291	Serum neutrophil gelatinaseâ€associated lipocalin correlates with kidney function in renal allograft recipients. Clinical Transplantation, 2009, 23, 681-686.	1.6	38
292	Hyporesponsiveness to Erythropoietin Therapy in Hemodialyzed Patients: Potential Role of Prohepcidin, Hepcidin, and Inflammation. Renal Failure, 2009, 31, 544-548.	2.1	20
293	Visfatin, a New Adipocytokine, Is Predominantly Related to Inflammation/Endothelial Damage in Kidney Allograft Recipients. Transplantation Proceedings, 2009, 41, 150-153.	0.6	24
294	Neutrophil Gelatinase-Associated Lipocalin Is a New and Sensitive Marker of Kidney Function in Chronic Kidney Disease Patients and Renal Allograft Recipients. Transplantation Proceedings, 2009, 41, 158-161.	0.6	79
295	Inadequate Blood Pressure Control in Most Kidney Transplant Recipients and Patients With Coronary Artery Disease With and Without Complications. Transplantation Proceedings, 2009, 41, 3069-3072.	0.6	17
296	A Possible Role of Hepcidin in the Pathogenesis of Anemia Among Kidney Allograft Recipients. Transplantation Proceedings, 2009, 41, 3056-3059.	0.6	15
297	Type of Renal Replacement Therapy and Residual Renal Function May Affect Prohepcidin and Hepcidin. Renal Failure, 2009, 31, 876-883.	2.1	19
298	Urinary and Serum Biomarkers after Cardiac Catheterization in Diabetic Patients with Stable Angina and without Severe Chronic Kidney Disease. Renal Failure, 2009, 31, 910-919.	2.1	86
299	Neutrophil Gelatinase-Associated Lipocalin in Dialyzed Patients Is Related to Residual Renal Function, Type of Renal Replacement Therapy and Inflammation. Kidney and Blood Pressure Research, 2009, 32, 464-469.	2.0	27
300	Structural changes in carotid arteries and impairment of fibrinolysis in hemodialyzed and peritoneally dialyzed patients. Medical Science Monitor, 2009, 15, CR644-9.	1.1	1
301	Kidney dysfunction after non renal solid organ transplantation. Annals of Transplantation, 2009, 14, 71-9.	0.9	5
302	Serum neutrophil gelatinaseâ€associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease. Nephrology, 2008, 13, 153-156.	1.6	63
303	Serum Neutrophil Gelatinase-Associated Lipocalin as a Marker of Renal Function in Non-Diabetic Patients with Stage 2â€“4 Chronic Kidney Disease. Renal Failure, 2008, 30, 625-628.	2.1	72
304	Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Advances in Medical Sciences, 2008, 53, 32-6.	2.1	34
305	Endothelial Function and Novel Adhesion Molecule CD44 in Kidney Allograft Recipients. Transplantation Proceedings, 2008, 40, 3470-3473.	0.6	10
306	Apelin, a Novel Adipocytokine, in Relation to Endothelial Function and Inflammation in Kidney Allograft Recipients. Transplantation Proceedings, 2008, 40, 3466-3469.	0.6	44

#	Article	IF	Citations
307	Prohepcidin in pregnancy: Acute phase protein, marker of iron metabolism, or both?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 140, 293-294.	1.1	2
308	Application of Myocardial Contrast Echocardiography for the Perfusion Assessment in Patients with End-Stage Renal Failure – Comparison with Coronary Angiography. American Journal of Nephrology, 2008, 28, 929-934.	3.1	3
309	Adipokines, Linking Adipocytes and Vascular Function in Hemodialyzed Patients, May Also Be Possibly Related to CD146, a Novel Adhesion Molecule. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 338-345.	1.7	9
310	Hepcidin is Linked to Anemia and Inflammation in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2008, 28, 418-421.	2.3	9
311	Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension. , 2008, 118, 36-41.		4
312	Hepcidin is linked to anemia and inflammation in peritoneal dialysis patients. Peritoneal Dialysis International, 2008, 28, 418-21.	2.3	7
313	Could Neutrophil-Gelatinase-Associated Lipocalin and Cystatin C Predict the Development of Contrast-Induced Nephropathy after Percutaneous Coronary Interventions in Patients with Stable Angina and Normal Serum Creatinine Values?. Kidney and Blood Pressure Research, 2007, 30, 408-415.	2.0	98
314	Hepcidin in Anemia and Inflammation in Chronic Kidney Disease. Kidney and Blood Pressure Research, 2007, 30, 15-30.	2.0	77
315	Markers of Bone Metabolism in Hemodialyses and Hemodiafiltration. Renal Failure, 2007, 29, 595-601.	2.1	4
316	Thyroid Function, Endothelium, and Inflammation in Hemodialyzed Patients: Possible Relations?. , 2007, 17, 30-37.		22
317	Elevated resistin is related to inflammation and residual renal function in haemodialysed patients. Nephrology, 2007, 12, 246-253.	1.6	23
318	134. American Journal of Kidney Diseases, 2007, 49, B58.	1.9	0
319	Possible Relations Between Thyroid Function, Endothelium, and Kidney and Liver Function in Kidney Allograft Recipients. Transplantation Proceedings, 2006, 38, 3509-3513.	0.6	14
320	Resistin, a New Adipokine, Is Related to Inflammation and Renal Function in Kidney Allograft Recipients. Transplantation Proceedings, 2006, 38, 3434-3436.	0.6	33
321	Value of the real-time myocardial contrast echocardiography for risk stratification and for the detection of significant coronary stenosis in patients with end-stage renal disease. Nephrology Dialysis Transplantation, 2006, 22, 668-669.	0.7	10
322	Undiagnosed renal impairment in patients with and without diabetes with normal serum creatinine undergoing percutaneous coronary intervention. Nephrology, 2006, 11, 549-554.	1.6	16
323	Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. American Journal of Hematology, 2006, 81, 832-837.	4.1	87
324	Neutrophil-Gelatinase-Associated Lipocalin and Renal Function after Percutaneous Coronary Interventions. American Journal of Nephrology, 2006, 26, 287-292.	3.1	215

#	Article	IF	Citations
325	Adiponectin, leptin and thyroid hormones in patients with chronic renal failure and on renal replacement therapy: are they related?. Nephrology Dialysis Transplantation, 2006, 21, 145-152.	0.7	49
326	Estimation of glomerular filtration rate in patients with normal serum creatinine undergoing primary PCI: is it really normal?. Nephrology Dialysis Transplantation, 2006, 21, 1736-1738.	0.7	11
327	Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum creatinine undergoing coronary angiography. Nephrology Dialysis Transplantation, 2006, 22, 295-296.	0.7	79
328	Apelin and Cardiac Function in Hemodialyzed Patients: Possible Relations?. American Journal of Nephrology, 2006, 26, 121-126.	3.1	40
329	Markers of endothelial damage in patients on hemodialysis and hemodiafiltration. Journal of Nephrology, 2006, 19, 150-4.	2.0	12
330	Renal transplant recipients with coronary artery disease exhibit impairment in fibrinolysis and structural changes in carotid arteries. Transplant International, 2005, 18, 256-259.	1.6	11
331	Markers of Endothelial Cell Activation/Injury: CD146 and Thrombomodulin Are Related to Adiponectin in Kidney Allograft Recipients. American Journal of Nephrology, 2005, 25, 203-210.	3.1	29
332	Is Hepcidin a Link between Anemia, Inflammation and Liver Function in Hemodialyzed Patients?. American Journal of Nephrology, 2005, 25, 586-590.	3.1	56
333	Cardiovascular risk in chronic renal disease and transplantation prevention and management. Expert Opinion on Pharmacotherapy, 2005, 6, 929-943.	1.8	7
334	Is there a link between CD146, a novel adhesion molecule and other markers of endothelial dysfunction in nephrotic syndrome and continuous ambulatory peritoneal dialysis?. Thrombosis Research, 2005, 115, 19-24.	1.7	8
335	Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy. Thrombosis and Haemostasis, 2004, 91, 480-486.	3.4	27
336	Endothelial Cell Injury Markers in Chronic Renal Failure on Conservative Treatment and Continuous Ambulatory Peritoneal Dialysis. Kidney and Blood Pressure Research, 2004, 27, 71-77.	2.0	39
337	THREE RUSSIAN DANCERS: DECADENCE, ART NOUVEAU, DEGENERATION. Experiment, 2004, 10, 115-132.	0.0	3
338	Adiponectin Is Related to CD146, a Novel Marker of Endothelial Cell Activation/Injury in Chronic Renal Failure and Peritoneally Dialyzed Patients. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4620-4627.	3.6	52
339	Comparison of Effects of Different Heparins on Thrombin Activatable Fibrinolysis Inhibitor in Hemodialyzed Patients. American Journal of Nephrology, 2004, 24, 624-629.	3.1	12
340	Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients. Blood Coagulation and Fibrinolysis, 2004, 15, 463-467.	1.0	16
341	Fluvastin therapy affects TAFI concentration in kidney transplant recipients. Transplant International, 2003, 16, 53-57.	1.6	12
342	Some aspects of hemostasis in kidney transplant recipients maintained on cyclosporine, azathioprine, and prednisone in comparison to patients treated with cyclosporine and prednisone. Transplantation Proceedings, 2003, 35, 2940-2942.	0.6	2

#	ARTICLE	IF	CITATIONS
343	Correlations of new markers of bone formation and resorption in kidney transplant recipients. Transplantation Proceedings, 2003, 35, 1351-1354.	0.6	10
344	Influence of simvastatin on aspects of thrombogenesis in CAPD patients. Peritoneal Dialysis International, 2003, 23, 260-6.	2.3	4
345	Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome. Blood Coagulation and Fibrinolysis, 2002, 13, 615-621.	1.0	27
346	Some Aspects of Hemostasis in CAPD Patients Treated with Erythropoietin. Kidney and Blood Pressure Research, 2002, 25, 240-244.	2.0	2
347	Vitamin K Status in Relation to Bone Metabolism in Patients with Renal Failure. American Journal of Nephrology, 2002, 22, 504-508.	3.1	26
348	Leptin Correlates with Some Hemostatic Parameters in CAPD Patients. Nephron, 2002, 92, 721-724.	1.8	17
349	Aluminium and beta-2-microglobulin in kidney transplant recipients. Transplantation Proceedings, 2002, 34, 580-582.	0.6	1
350	Correlations between new markers of bone formation versus bone resorption in kidney transplant recipients. Transplantation Proceedings, 2002, 34, 591-592.	0.6	2
351	Parathyroid gland sonography in relation to markers of bone metabolism in kidney transplant recipients. Transplantation Proceedings, 2002, 34, 593-595.	0.6	3
352	Parvovirus B19 infection and IGF system components in relation to erythropoiesis in dialyzed patients and kidney transplant recipients. Transplantation Proceedings, 2002, 34, 3211-3214.	0.6	6
353	A Comprehensive Study on Hemostasis in CAPD Patients Treated with Erythropoietin. Peritoneal Dialysis International, 2002, 22, 582-592.	2.3	14
354	Insulin-Like Growth Factor System Components in Relation to Erythropoietin Therapy and Bone Metabolism in Dialyzed Patients and Kidney Transplant Recipients. Nephron, 2002, 90, 282-289.	1.8	6
355	Effects of fluvastatin on homocysteine and serum lipids in kidney allograft recipients. Annals of Transplantation, 2002, 7, 52-4.	0.9	2
356	Effects of immunosuppressive drugs on platelet aggregation in vitro. Annals of Transplantation, 2002, 7, 55-68.	0.9	7
357	A comprehensive study on hemostasis in CAPD patients treated with erythropoietin. Peritoneal Dialysis International, 2002, 22, 582-92.	2.3	6
358	Patients on Peritoneal Dialysis But Not on Hemodialysis Have Elevated Concentration and Activity of Thrombin-Activatable Fibrinolysis Inhibitor. Thrombosis Research, 2001, 104, 233-238.	1.7	19
359	Comparison of Hemostatic Disturbances between Patients on Capd and Patients on Hemodialysis. Peritoneal Dialysis International, 2001, 21, 158-167.	2.3	66
360	Simvastain Affects TAFI and Thrombomodulin in CAPD Patients. Thrombosis and Haemostasis, 2001, 86, 930-931.	3.4	12

#	Article	IF	Citations
361	Serum Crosslaps Correlations with Serum ICTP and Urine DPD in Hemodialyzed and Peritoneally Dialyzed Patients. Nephron, 2001, 87, 283-285.	1.8	8
362	Effects of Long-Term Treatment with Simvastatin on Some Hemostatic Parameters in Continuous Ambulatory Peritoneal Dialysis Patients. American Journal of Nephrology, 2001, 21, 373-377.	3.1	11
363	Correlation between carotid intima-media thickness and hematocrit and hemoglobin values in renal transplant recipients. Clinical Transplantation, 2001, 15, 349-353.	1.6	7
364	A possible role of thrombinâ€activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. Nephrology Dialysis Transplantation, 2001, 16, 1692-1696.	0.7	22
365	Leptin and Serum Erythropoietin in Hemodialyzed and Peritoneally Dialyzed Uremic Patients during rHuEPO Therapy. American Journal of Nephrology, 2000, 20, 180-186.	3.1	6
366	Peripheral Serotonergic System in Hemodialyzed and Peritoneally Dialyzed Patients. Nephron, 2000, 86, 396-397.	1.8	1
367	Leptinaemia in patients dialysed with different buffers and dialysis membranes. Nephrology Dialysis Transplantation, 1999, 14, 2527-2529.	0.7	2
368	A Potent 5-Hydroxytryptamine Receptor (5-HT2A) Antagonist, DV-7028, Delays Arterial Thrombosis Development in Rats. Thrombosis Research, 1998, 90, 259-270.	1.7	18
369	Vascular and Cardiac Effects of DV-7028, a Selective, 5-HT2-Receptor Antagonist in Rats. Journal of Cardiovascular Pharmacology, 1998, 32, 266-273.	1.9	18
370	Effects of short-term treatment with mevalotin on platelet aggregation, fibrinolysis, peripheral serotonergic system and serum lipids in Japanese monkeys. Thrombosis Research, 1996, 81, 397-402.	1.7	3
371	Changes in serotonergic measures in whole blood and various brain regions of rats administered with the 5-HT1A agonist tandospirone and/or exposed to electric foot-shock. Brain Research Bulletin, 1996, 40, 51-55.	3.0	3
372	Plasma Serotonin and Platelet Aggregation during Ischemia-Reperfusion in Dogs: Effect of Dipyridamole and Coenzyme Q₁₀. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 38-44.	0.3	3
373	Renal Blood Flow and Serotonin Metabolism in Tacrolimus Treated Rats. International Journal of Urology, 1996, 3, 187-190.	1.0	11
374	THE COAGULO-LYTIC SYSTEM AND ENDOTHELIAL FUNCTION IN CYCLOSPORINE-TREATED KIDNEY ALLOGRAFT RECIPIENTS. Transplantation, 1996, 62, 828-830.	1.0	70
375	Close Relationships between Serotonergic and Fibrinolytic Systems Revealed by a Monoamine Oxidase Inhibitor Treatment in Rats. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1995, 25, 277-282.	0.3	0
376	Renal blood flow, fibrinolysis, and platelet aggregation following tacrolimus (FK 506) treatment in rats. Thrombosis Research, 1995, 79, 337-341.	1.7	4
377	Amino acids, serotonin, and 5-hydroxyindoleacetic acid following foot shock in rats. Brain Research Bulletin, 1995, 36, 137-140.	3.0	16
378	Serotonergic systems in brain and blood under stress and tranylcypromine treatment in rats. Brain Research Bulletin, 1994, 35, 9-13.	3.0	6

#	Article	IF	Citations
379	Fibrinolysis and serotonin under cyclosporine a treatment in renal transplant recipients. Thrombosis Research, 1994, 76, 97-102.	1.7	13
380	Stress-dependent changes in fibrinolysis, serotonin and platelet aggregation in rats. Life Sciences, 1994, 54, 1275-1280.	4.3	15
381	Serotonergic mechanisms are involved in the hemostatic action of erythropoietin in uremic patients. International Journal of Clinical and Laboratory Research, 1993, 23, 42-44.	1.0	9
382	Possible Involvement of Serotonin in the Haemostatic Action of DDAVP in Patients with Uraemia. , 1993, , 35-41.		0
383	First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland. F1000Research, 0, 10, 841.	1.6	1
384	Acute kidney injury prevalence in patients with colorectal cancer undergoing surgery with curative intent. Wspolczesna Onkologia, 0, , .	1.4	1